Clinical Management of Cancer-Related Cachexia: Review of the Literature
DOI:
https://doi.org/10.17140/PMHCOJ-1-106Keywords:
Cachexia, Interleukins, Metabolic syndrome, Hypercatabolic state, Anorexia-cachexiaAbstract
Cachexia is among the most debilitating and life-threatening aspects of cancer, especially in the palliative care setting. It represents a metabolic syndrome affecting essential functional circuits involved in the regulation of homeostasis, with symptoms including anorexia, and fat and muscle tissue wasting. Most patients experiencing cachexia do not receive proper management and suffer a profoundly distressing experience, affecting not only the patients, but also the entire family. Thus, oncologists and palliative care clinicians must understand its complex pathophysiology and treatment. This article will review special considerations about the anorexia-cachexia syndrome and which interventions are most effective in relieving this condition.
References
Kotler DP. Cachexia. Ann Intern Med. 2000; 133(8): 622. doi: 10.7326/0003-4819-133-8-200010170-00015
Ma G, Alexander H. Prevalence and pathophysiology of can-cer cachexia. In: Bruera E, Portenoy R K. Topics in Palliative Care. New York, NY, USA: Oxford University Press; 1998: 91- 129.
Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol. 1997; 24(3): 277-287.
Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutrition-al status in advanced metastatic cancer. Support Care Cancer. 2003; 11(10): 652-659. doi: 10.1007/s00520-003-0486-0
Del Fabbro E, Hui D, Dalal S, et al. Clinical outcome and con-tributors to weight loss in cancer cachexia Clinic. J Palliat Med. 2011; 14(9): 1004-1008. doi: 10.1089/jpm.2011.0098
Chochinov HM, Hack T, Hassard T, Kristjanson LJ, Mc-Clement S, Harlos M. Dignity in the terminally ill: a cross-sec-tional, cohort study. Lancet. 2002; 360(9350): 2026-2030. doi: 10.1016/S0140-6736(02)12022-8
Langstein HN, Norton JA. Mechanisms of cancer cachexia. Hematol Oncol Clin North Am. 1991; 5(1): 103-123.
Todorov P, Cariuk P, McDevitt T, et al. Characterization of cancer cachectic factor. Nature. 1996; 379: 739-742. doi: 10.1038/379739a0
Walsh D, Mahmoud F, Barna B. Assessment of nutritional sta-tus and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer. 2003; 11(1): 60-62. doi: 10.1007/s00520- 002-0390-z
Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008; 27(6): 793-799. doi: 10.1016/j. clnu.2008.06.013
Fearon K, Arends J, Baracos V. Understanding the mecha-nisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013; 10(2): 90-99. doi: 10.1038/nrclinonc.2012.209
Lucia S, Esposito M, Rossi Fanelli F, Muscaritoli M. Can-cer cachexia: From molecular mechanisms to patient’s care. Crit Rev Oncog. 2012; 17(3): 315-321. doi: 10.1615/CritRevOncog. v17.i3.90
Chasen M, Bhargava R, Hirschman S. Immunomodula-tory agents for the treatment of cachexia. Curr Opin Sup-port Palliat Care. 2014; 8(4): 328-333. doi: 10.1097/ SPC.0000000000000086
DeVita, Hellman, Rosenberg. Cancer: Principles and Prac-tice of Oncology. Philadelphia, PA 19103, USA: J.B. Lippincott Company; 1982.
Fearon K, Strasser F. Definition and classification of can-cer cachexia: an international consensus. Lancet Oncol. 2011; 12(5): 489-495. doi: 10.1016/S1470-2045(10)70218-7
Kwang AY, Kandiah M. Objective and subjective nu-tritional assessment of patients with cancer in palliative care. Am J Hosp Palliat Care. 2010; 27(2): 117-126. doi: 10.1177/1049909109353900
Simons JP, Schols AM, Westerterp KR, ten Velde GP, Wout-ers EF. The use of bioelectrical impedance analysis to predict to-tal body water in patients with cancer cachexia. Am J Clin Nutr. 1995; 61(4): 741-745.
Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in can-cer patients using computed tomography images acquired dur-ing routine care. Applied Physiology, Nutrition, and Metabolism. 2008; 33(5): 997-1006. doi: 10.1139/H08-075
Fearon K, Arends J, Baracos V. Understanding the mecha-nisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013; 10(2): 90-99. doi: 10.1038/nrclinonc.2012.209
Del Fabbro E. More is better: a multimodality approach to cancer cachexia. Oncologist. 2010; 15(2): 119-121. doi: 10.1634/ theoncologist.2010-0019
Body JJ. The syndrome of anorexia-cachexia. Curr Opin Oncol. 1999; 11: 255-260.
Ottery FD, Walsh D, Strawford A. Pharmacologic manage-ment of anorexia/cachexia. Semin Oncol. 1998; 25(Suppl 6): 35- 44.
Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol. 2001; 12(3): 289-300.
Berenstein EG, Oritz Z. Megestrol acetate for the treat-ment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005; (2): CD004310. doi: 10.1002/14651858.CD004310. PUB2
Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospec-tive randomized double-blind study. Cancer Treat Rep. 1985; 69(7-8): 751-754.
Yennurajalingam S, Frisbee-Hubbe S, Palmer JL, et al. Re-duction of cancer-related fatigue with dexamethasone: a dou-ble-blind, randomized, placebo controlled trial inpatients with advanced cancer. J Clin Oncol. 2013; 31(25): 3076-3082. doi: 10.1200/JCO.2012.44.4661
Cannabis-In-Cachexia-Study-Group1, Strasser F, Luftner D, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006; 24(21): 3394-3400. doi: 10.1200/JCO.2005.05.1847
Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. Gut. 2005; 54(4): 540. doi: 10.1136/gut.2004.047563
Laviano A, Muscaritoli M, Cascino A, et al. Branched chain amino acids: the best compromise to achieve anabolism. Curr Opin Clin Nutr Metab Care. 2005; 8(4): 408-414.
Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acidon weight loss in patients with pancreatic cancer. Nutr Cancer. 2000; 36(2): 177-184. doi: 10.1207/S15327914NC3602_6
Ravasco P, Monteiro Grillo I, Camilo M. Cancer wasting and quality of life react to early individualized nutritional counseling. Clin Nutr. 2007; 26(1): 7-15. doi: 10.1016/j.clnu.2006.10.005
Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sar-copenia Muscle. 2013; 4(2): 95-109. doi: 10.1007/s13539-012- 0087-1
Davis MP, Khawam E, Pozuelo L, Lagman R. Manage-ment of symptoms associated with advanced cancer: olan-zapine and mirtazapine. A World Health Organization Proj-ect. Expert Rev Anticancer Ther. 2002; 2(4): 365-376. doi: 10.1586/14737140.2.4.365
Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival and quality of life in cancer patients un-dergoing chemotherapy: a prospective, randomized study. J Clin Oncol. 1993; 11(10): 2043-2049.
Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with ad-vanced cancer and cachexia: A double-blind placebo-controlled trial. J Clin Oncol. 2013; 31(10): 1271-1276. doi: 10.1200/ JCO.2012.43.6766
Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Ca-chexia Sarcopenia Muscle. 2014; 5(4): 329-337. doi: 10.1007/ s13539-014-0159-5
Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer. 2008; 16: 447-451. doi: 10.1007/s00520-007-0388-7
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Palliative Medicine and Hospice Care (PMHC) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
